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Purpose: To investigate whether a combination of self-expanding metal stent (SEMS) and brachytherapy
provided more rapid and prolonged effect on dysphagia without increased pain compared to brachyther-
apy alone in patients with incurable oesophageal cancer.
Methods: 41 Patients were randomised to SEMS followed by brachytherapy, 8 Gy  3 (n = 21) or brachy-
therapy alone, 8 Gy  3 (n = 20). Change in dysphagia and pain three and seven weeks after randomisa-
tion (FU1 and FU2) was assessed by patient-reported outcome. Dysphagia, other symptoms and health-
related quality of life were assessed every four weeks thereafter. The study was closed before the esti-
mated patient-number was reached due to slow recruitment.
Results: Patients receiving SEMS followed by brachytherapy had signiﬁcantly improved dysphagia at FU1
compared to patients receiving brachytherapy alone (n = 35). Difference in pain was not observed. At FU2,
patients in both arms (n = 21) had less dysphagia. Four patients in the combined treatment arm experi-
enced manageable complications, no complications occurred after brachytherapy alone.
Conclusion: For the relief of dysphagia, SEMS followed by brachytherapy is preferable and safe for
patients in need of immediate alleviation, while brachytherapy with or without preceding SEMS provides
relief within a few weeks after treatment.
 2013 Elsevier Ireland Ltd. Radiotherapy and Oncology 107 (2013) 428–433 Open access under CC BY-NC-NDIn patients with advanced cancer of the oesophagus, the poor
prognosis is associated with advanced stage of the disease, reduced
performance status (PS), and weight loss [1,2]. In a retrospective
palliative study, the median survival was shorter for patients with
WHO PS = 2 (three months) compared to patients with WHO PS 0–
1 (six months) [3]. Such patients need palliative interventions with
high efﬁcacy, short treatment duration and few side effects.
Common treatments for the alleviation of dysphagia are stent
placement, external radiotherapy, brachytherapy and chemother-
apy, but the optimal intervention has yet not been established. Sys-
tematic comparisons of different modalities are rare [4,5]. In a trial
of 209 patients, dysphagia improved more rapidly using self-
expanding metal stents (SEMS) than with single dose brachyther-
apy (12 Gy). The effect, however, lasted longer with brachytherapy
[6]. Similar results were obtained in another study (n = 65) of SEMS
versus fractionated brachytherapy (7 Gy  3) [7]. Both studies re-
ported more complications with SEMS than with brachytherapy,
and patients in the brachytherapy arm reported better quality of
life after treatment.ncer Medicine, Surgery and
iversity Hospital, Norwegian
, Norway.
der CC BY-NC-ND license.At the Norwegian Radium Hospital, fractionated brachytherapy
(8 Gy  3) or SEMS placement was standard palliative treatment
for oesophageal cancer patients with dysphagia and reduced PS.
Applicators designed to be used inside stents, allowing central
positioning of the radioactive probe, were available from 2008.
Based on the two studies above, a randomised trial comparing
SEMS followed by brachytherapy versus brachytherapy alone was
initiated.
The primary aim was to assess by patient-reported outcomes
(PROs) whether SEMS followed by brachytherapy gave patients im-
proved dysphagia without more pain at the ﬁrst follow-up three
weeks after randomisation (FU1), compared to patients who re-
ceived brachytherapy alone. Secondary aims were to explore dif-
ferences between the treatment arms at the second follow-up,
seven weeks after randomisation (FU2) in: dysphagia, pain, treat-
ment feasibility, weight and selected health related quality of life
(HRQL) parameters; global quality of life, emotional function, dys-
phagia, and eating restrictions.
Methods
Patients and study design
Patients from the south-eastern region of Norway, with incura-
ble carcinoma of the oesophagus and dysphagia grade 1–4, who
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eligible for inclusion (Fig. 1). Patients with residual or progressive
disease after primary treatment were also candidates. Exclusion
criteria were tumour located at the pharyngo-oesophageal junc-
tion or with the major component in the gastric cardia, and pa-
tients with contraindications for further radiotherapy or stent
placement. Based on a previous study [3], we expected 30 eligible
patients per year.
The design was a prospective, two-armed phase III trial. The pa-
tients were randomised by our Clinical Trials Unit using computer-
based real time permuted block randomisation to either arm A:
SEMS followed by brachytherapy (experimental arm) (n = 21) or
arm B: Brachytherapy alone (standard arm) (n = 20).
The study was approved by the Regional Ethics Committee and
the hospital’s local authorities. Written informed consent and a
completed patient questionnaire were obtained before
randomisation.Procedures
Stent placement
Covered SEMS were used in Arm A. The proximal and distal tu-
mour margins were measured endoscopically and marked with
metal pellets on the patient’s skin guided by ﬂuoroscopy. After
the stent was inserted, the position was controlled endoscopically
and with ﬂuoroscopy.
Brachytherapy
A ﬂexible applicator (Bonvoisin-Gérard Esophageal Applicator
Set Nucletron, Veenendal, The Netherlands) with a diameter
(15 mm, 13 mm or 10 mm) that best ﬁtted the stent diameter
(Arm A) or oesophageal lumen diameter (Arm B) was introduced
into the oesophagus. A metal wire with radiopaque markers atFig. 1. Trial proﬁle.1 cm interval was inserted into the applicator and the position of
the applicator was adjusted by ﬂuoroscopy. The treatment length
included the tumour with an inferior and superior margin of one
centimetre. In the radiotherapy department, the applicator was
connected to a MicroSelectron afterloading device with a step-
ping source of Iridium-192. A dose of 8 Gy was prescribed at seven
millimetres depth from the surface of the applicator. The duration
of radiation for each patient (5–25 min) depended on the source
strength, the length of treatment volume and the applicator diam-
eter. Three fractions of 8 Gy were given at one-week intervals.
Brachytherapy started the week after stent insertion in arm A.
In a pilot study using three dimensional image guided brachy-
therapy, the precision of treatment was not improved and conven-
tional treatment planning was used in this trial.
All patients received intravenous sedation and analgesics dur-
ing the procedure. They were allowed to drink one hour after treat-
ment. Most patients left the hospital within a few hours after the
procedure.Clinical characteristics and observer-rated outcomes
Stage of disease was based on the TNM classiﬁcation of malig-
nant tumours [8]. The extent of disease, the WHO PS, weight
change, use of analgesics and selected symptoms and signs accord-
ing to the NCI-CTCAE [9] were recorded at the time of inclusion,
FU1 and FU2. The dysphagia was scored as follows: score 0; ability
to eat a normal diet without problems, score 1; ability to eat some
solid food, score 2; ability to eat semisolid food, score 3; ability to
drink only, score 4; complete dysphagia [10]. Complications
requiring an intervention or prolonged stay in hospital were re-
corded for each treatment session.
All patients received weekly telephone-calls from the study
coordinator or study nurse from the end of treatment to FU2,
and thereafter every four weeks until death. At FU2, endoscopy
was performed if needed. Patients in Arm B with persistent or in-
creased dysphagia were offered SEMS at FU2, and if, at a later time
point, they had relapse of dysphagia, they were offered a SEMS at
their local hospital. Days in hospital from randomisation until
death were registered.Patient-reported outcomes (PROs)
A set of questionnaires consisting of a dysphagia grading scale, a
symptom assessment scale and two HRQL questionnaires was
completed by the patient at the hospital before randomisation
and at FU1. Later, it was mailed to the patients every four weeks
until death, withdrawal of consent for PRO-part of study or end
of study.
The dysphagia grading scale [10] has been used as patient-re-
ported measure of dysphagia [5]. The Edmonton Symptom Assess-
ment Scale (ESAS) is developed to measure symptoms in palliative
patient populations [11]. Aspects of HRQL for cancer patients in
general is covered by the European Organisation for Research
and Treatment of Cancer (EORTC) Quality of Life Questionnaire
Core 30 version 3 (EORTC QLQ-C30) [12,13]. It comprises ﬁve func-
tional scales (physical, role, cognitive, emotional and social), three
symptom scales (fatigue, nausea/vomiting and pain), six single
items and a global quality of life scale. The EORTC oesophagoga-
stric speciﬁc module (EORTC QLQ-OG25) contains six symptom
scales (dysphagia, eating restrictions, reﬂux, odynophagia, pain
and discomfort, and anxiety), and 10 single items. Both HRQL ques-
tionnaires are validated for use in oesophageal cancer patients
[14].
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Primary endpoints; change in patient-reported dysphagia and
pain at rest measured by the dysphagia grading scale and ESAS
from inclusion to FU1. Three weeks after inclusion was selected
as FU1 in order to capture the maximum toxicity after SEMS and
to measure effect while the compliance still was sufﬁcient in a pa-
tient group with high attrition due to death. Secondary endpoints;
change in patient-reported dysphagia (dysphagia grading scale)
and pain at rest (ESAS) at FU2. Patient-reported change in emo-
tional function and global quality of life measured by EORTC
QLQ-C30 and dysphagia and eating restrictions measured by
EORTC QLQ-OG25 were assessed. Differences in treatment feasibil-
ity and patients’ weight change from baseline to FU2 were also ex-
plored. Other PRO data are presented of descriptive purposes.Statistical methods
Descriptive statistics are presented as means or medians with
ranges as appropriate. Differences between groups were tested
by Chi-square tests (linear-by-linear associations).
Survival was calculated as the number of days from randomisa-
tion to death or censored on 01.08.2012 if alive. Survival was esti-
mated using the Kaplan–Meier method and comparison of the two
treatment groups was done by the log rank test.
In a sample size calculation, it was estimated that 64 patients
were needed to detect a difference in change of dysphagia at
FU1. This was based on the assumption that the expected propor-
tion of patients with improved dysphagia was 90% in arm A and
60% in arm B (signiﬁcance level: 0.05, power 80%). However, theTable 1
Patient characteristics at baseline.
Total n
Age (years) Mean (range) 74 (47
Sex Male/female 26/15
Stage of disease Local (T1-T3N0) 2
Locally advanced (T1-T4N1/T4N0) 39
Distant metastases (M1) 18
Tumour length (cm) Mean (range) 7 (3–1
Tumour localisation Proximal 1/3 2
Middle 1/3 11
Lower 1/3 27
Overlap middle – lower 1
Histology Adenocarcinoma 25
Squamous cell carcinoma 14
Carcinoma, unclassiﬁed 2
State of disease Primary disease 35
Relapse/progression 6
WHO performance status 0/1 14
2 23
3/4 4
Weight loss 65% 9
>5% 30
Missing 2
Analgesics None 22
Non-opioids only 8
Opioids+/non-opioids 11
Patient reported outcomes
Dysphagia (grading scale) Normal diet (0) 0
Discomfort (1) 9
Soft diet (2) 17
Fluids only (3) 12
Full stop (4) 3
Pain at rest (ESAS) None (0) 26
Mild (1–3) 11
Moderate (4–6) 4
Severe (7–10) 0study was closed before the estimated number of patients was in-
cluded due to slow patient recruitment. Based on the small num-
ber of patients, only a limited number of tests have been
performed and caution has been taken not to make strong conclu-
sions based on non-signiﬁcant results.
Standard algorithms provided by the EORTC Quality of life
group [15] were used. The patients answered scales with Likert
type response categories ranging from 1 (not at all) to 4 (very
much) or from 1 (very poor) to 7 (excellent) (global questions 29
and 30). All scores were linearly transformed to a 0–100 scale
where a high score represents a high degree of function or a high
degree of side effects/problems. For every scale, the mean value
was calculated. Clinically signiﬁcant response on an EORTC scale
is deﬁned as a change ofP10, while the situation is said to be un-
changed if the change is <10 [16]. Missing items were handled
according to the EORTC QLQ-C30 scoring manual [15]. ESAS had re-
sponse scales ranging from no (0) to the worst possible (10) prob-
lems, and for each score a change of two steps was considered
clinically signiﬁcant.Results
The baseline characteristics of the two treatment groups SEMS
followed by brachytherapy (arm A) and brachytherapy alone
(arm B), were similar for most variables (Table 1).Primary and secondary PRO
Signiﬁcantly more patients in arm A (12/17) than in arm B (7/
18) reported improved dysphagia without a signiﬁcant difference= 41 Stent + brachytherapy n = 21 Brachytherapy alone n = 20
–91) 73 (59–90) 74(47–91)
13/8 13/7
1 1
20 19
9 9
3) 8 (5–13) 7 (3–13)
1 1
5 6
15 12
0 1
12 13
7 7
2 0
17 18
4 2
4 10
14 9
3 1
4 5
16 14
1 1
11 11
2 6
8 3
0 0
3 6
8 9
8 4
2 1
13 13
6 5
2 2
0 0
Table 2
Change in patient-reported dysphagia and pain from baseline to FU1 (week 3) and from baseline to FU2 (week 7).a
FU1 evaluation Change score Stent + brachytherapy n = 17 Brachytherapy alone n = 18 p-Valueb
Dysphagia Mean change (range) 1 (1, 3) 0 (1, 1)
Proportion of Improved 3 1/17 0/18
patients 2 4/17 0/18
1 7/17 7/18 0.02
Unchanged 0 4/17 9/18
Worse or always full stop 1 1/17 2/18
Pain Mean change (range) 1 (0, 9) 1 (2, 3)
Proportion of Improved 0/17 1/18
patients Always no pain 7/17 7/18 0.3
Unchanged 6/17 5/18
Worse 4/17 5/18
FU2 evaluation Change score Stent + brachytherapy n = 9 Brachytherapy alone n = 12
Dysphagia Mean change (range) 1 (1, 3) 1 (0, 4)
Improved 1–3 7/9 10/12
Proportion of Unchanged 0 1/9 2/12
patients Worse or always full stop 1 1/9 0/12
Pain Mean change (range) 2 (1,8) 1 (1,4)
Always no pain 2/9 4/12
Proportion of Improved 0/9 0/12
patients Unchanged 3/9 5/12
Worse 4/9 3/12
a Different populations due to attrition.
b Linear-by linear association (2-sided).
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At FU2, most evaluable patients in both groups reported improved
dysphagia (17/21) (Table 2). A corresponding clinically signiﬁcant
improvement was found for aspects of HRQL connected to eating
measured by EORTC QLQ-OG25 (dysphagia scale, eating restriction
scale) (Supplementary Table). No signiﬁcant differences were
found between the treatment arms for the EORTC HRQL scales ex-
plored (emotional function, global quality of life, dysphagia and
eating restrictions) Odynophagia, eating in front of others and dry-
ness of the mouth improved while most of the other aspects of
HRQL deteriorated or remained low (Supplementary Table).Compliance and patient-reported dysphagia
The number of patients/of those alive, ﬁlling in questionnaires
at FU1, FU2, Week 11 and week 15, were 35/37, 21/32, 16/24
and 13/19 respectively. Most patients (33/41) continued to ﬁll in
the questionnaires near up to (last or second last FU) the time of
death, but the short survival resulted in rapid attrition of patients
(Supplementary Figure).The majority of patients (10/13 at week
15) with initial relief of dysphagia continued to have the effect of
treatment close until death.Fig. 2. Overall survival by treatment arm (p = 0.6).Survival and treatment feasibility
Median survival was 14 weeks for the total group without sta-
tistical signiﬁcant difference between patients in arm A (11 weeks)
and arm B (18 weeks) (Fig. 2). One patient was alive and censored
at the closure of study. All the others (n = 40) died of their index
cancer.
The study treatment was completed by 34 patients; 15 in arm A
and 19 in arm B (Fig. 1). Treatment was delayed for one patient due
to fever and for three patients because of administrative reasons.
Mean duration (range) of treatment was 20 days (14–24) for arm
A and 14 days (11–20) for arm B. Half of the patients (17/34) com-
pleted the treatment as outpatients with three to four visits at the
hospital. The procedure started after lunchtime and 10 patients
had to stay overnight because of practical reasons.
Complications of treatment occurred in arm A only; aspiration
pneumonia (n = 2), aspiration pneumonia and bleeding (n = 1)and stent dislocation during brachytherapy (n = 1). There were no
perforation or ﬁstula formations. All complications, except the
stent dislocation, resulted in prolonged stay in hospital, but none
were life-threatening and all were successfully treated. Symptoms
at the end of treatment, (oesophagitis, heartburn, strictures, chest
pain, nausea, vomiting, constipation, diarrhoea, cough and dysp-
noea) were in general mild. However, 19 patients had grade 3 fati-
gue and 10 patients had grade 3 anorexia.Clinical evaluation at FU2 and thereafter
More patients were available for the observer-rated evaluation
(n = 33), than the patient-reported part (n = 21) of the study. Im-
proved observer-rated dysphagia was found for 17 of the 33 pa-
tients while 13 patients were unchanged. Differences between
groups were not observed. Chest pain increased from baseline for
432 Brachytherapy in advanced oesophageal cancer13 patients, while ﬁve had less pain. All of them were treated with
analgesics.
A large proportion of patients (23/33) had irreversibly reduced
PS and 3/4 of the patients with PS 3 at baseline died before FU2.
Body weight was available for 28 patients both at the baseline
and FU2 and 16 had weight loss. Difference between the treatment
arms was not seen.
Endoscopic evaluation at FU2 was performed in 14 patients in
arm B; four of these were in need of SEMS. Another eight of the
20 patients in arm B, later received SEMS at median (range)
12 weeks (6–43) from the end of treatment. Eight patients never
received a SEMS. In arm A, three patients needed a second SEMS,
12, 24 and 28 weeks after the end of treatment.
A total of 21 of the 33 patients did not need hospital admission
between the end of treatment and FU2. After FU2, eight patients
had no hospitalisation, seven had fewer than seven hospital days
but six patients used more than 1=4 of their remaining life time in
hospital.Discussion
This is the ﬁrst randomised trial comparing SEMS followed by
brachytherapy vs brachytherapy alone for relief of dysphagia in pa-
tients with oesophageal cancer. Such a trial has been asked for
[17,18]. Despite reduced power in the study, a clinical and statisti-
cally signiﬁcant difference between the arms was found for the pri-
mary endpoint in favour of SEMS followed by brachytherapy. We
demonstrated that the immediate effect of SEMS could be com-
bined with the more longstanding effect of brachytherapy. In
accordance with others [17,19], we believe that this combination
is feasible, safe and superior to brachytherapy alone in the initial
relief of dysphagia. In accordance with these results, the clinical
practise at our institution is now being changed.
Due to the toxicity of SEMS followed by brachytherapy, this
treatment might be limited to patients who need immediate alle-
viation of dysphagia. The additional effect of SEMS was most prom-
inent during the ﬁrst weeks of treatment. For patients who are able
to eat semi-solid food and can wait a few weeks for the effect,
brachytherapy alone might be better. On the other hand, the ﬁve
complications seen in four of the 21 patients in arm A had no seri-
ous implications.
It was reassuring that most patients living more than three
months, had maintained improvement of dysphagia. The high
proportion of patients in arm B later receiving a SEMS (12 of 20 pa-
tients) shows that brachytherapy alone has limitations. Therefore,
regular clinical follow-ups are needed and patients with persistent
or recurrent dysphagia should be offered a SEMS.
Median survival of our patients was shorter than in other brach-
ytherapy trials [6,17] indicating that they had more advanced dis-
ease. Brachytherapy may be the treatment of choice for a larger
group of patients with cancer of the oesophagus and dysphagia.
In a trial published in 2010, brachytherapy (8 Gy  2) followed
by external radiotherapy (3 Gy  10) was compared with brachy-
therapy alone (8 Gy  2) [20]. The combination was superior in re-
lief of dysphagia. The disadvantage of external radiotherapy is the
length of the treatment period, and we are reluctant to believe that
external radiotherapy is beneﬁcial for patients with life-expec-
tancy shorter than six months. We would rather suggest re-treat-
ment of patients with persistent dysphagia due to tumour
obstruction. Our patients spent a few days in hospital. A further
reduction in treatment time by using a shorter brachytherapy
schedule would be an advantage. Currently, there is no interna-
tional consensus on the optimal fractionation. Two trials with a
comparison of two fractionation regimens; 6 Gy  3 vs 8 Gy  2,
showed similar efﬁcacy in palliation of dysphagia [21,22]. Thesecond regimen, shortened the time period by giving treatment
on alternate days instead of weekly. Alternatively, single-dose
brachytherapy, 12 Gy  1, with one outpatient procedure, is efﬁ-
cient and safe [6,17]. The effect of fractionated brachytherapy vs
single-dose brachytherapy has not been published [23].
It is difﬁcult to distinguish between toxicity of treatment and
symptoms of a progressive disease. Severe fatigue and appetite loss
were frequently reported both at baseline and at the end of treat-
ment. Many patients continued to lose weight despite relief of dys-
phagia and improved eating ability. The irreversibility of the
weight loss, anorexia and fatigue suggest that these patients suffer
from primary cachexia rather than undernutrition. Therefore, it is
important to communicate to the patients that the planned treat-
ment aims to relieve dysphagia, but will not necessarily improve
weight loss, appetite or fatigue. Nevertheless, we believe that it
is of value for the patients’ general well-being to be able to swal-
low until death.
Corresponding results were found for HRQL. The improved as-
pects of HRQL were connected to eating while most of the other as-
pects of HRQL including anorexia and fatigue deteriorated
irreversibly. This is in line with results found for similar patient
groups [7,17].
In accordance with recommendations [24], predeﬁned PRO was
included both as primary and secondary endpoints. Survival was
included as a secondary endpoint, in order not to miss a non-ex-
pected survival difference. A completed patient-questionnaire as
one of the inclusion criteria ensured 100% compliance from start.
Unfortunately, the rapid attrition of patients made it impossible
to explore differences between groups over time.
The slow patient recruitment was due to more patients being
treated at the radiotherapy units closer to home and reorganisation
of our hospital. There was a shift in the multidisciplinary team’s
preference in favour of chemotherapy even though there are no
publications comparing the effect of chemotherapy vs brachyther-
apy or other interventions for dysphagia [5]. A few phase II studies
have reported relief of dysphagia after chemotherapy [25,26].
Conclusions
SEMS followed by brachytherapy is preferable and safe for pa-
tients in need of immediate alleviation of dysphagia. Brachyther-
apy with or without preceding SEMS provide relief of dysphagia
within a few weeks. Improvement of aspects of HRQL not related
to eating cannot be expected and patients should be informed
thereof.
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